The patients aged 60 years and over and patients were diagnosed with Acute Myeloid Leukemia according to the 2016 World Health Organization criteria.The patient was diagnosed with acute promyelocytic Non-inferiority , Low-dose cytarabine ,hydroxyurea , Acute Myeloid Leukemia
Conditions
Interventions
The patients aged 60 years and over and patients were diagnosed with Acute Myeloid Leukemia according to the 2016 World Health Organization criteria.The patient was diagnosed with acute promyelocytic
RARA and the patient was assessed by the treating physician that his condition could be administered with a standard chemotherapy regimen such as ECOG less than 2,
cardiac ejection fraction. 50 checked by echocardiogram or MUGA
Diagnostic
Patients aged 60 years and over and patients were diagnosed with Acute Myeloid Leukemia according to
Sponsors
Siriraj Hospital Mahidol University
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: New patients Who were diagnosed with acute myeloid leukemia in accordance with the 2016 World Health Organization criteria and patients aged 60 and over.
Exclusion criteria
Exclusion criteria: The patient was diagnosed with acute promyelocytic leukemia with PML-RARA, the patient was assessed by the treating physician that his physical condition was able to administer standard chemotherapy drugs such as ECOG less than 2, cardiac ejection fraction greater than 50. Examined by echocardiogram or MUGA scan, patients can access drug groups. Patients with hypomethylating agent pre-treatment are within the following requirements:Serum creatinine level greater than 2 mg / dl TB level is more than 2 times normal AST / ALT level is more than 3 times the value. normal Patients with treatment plans for bone marrow transplantation Patients with sepsis Or the physician in charge of suspecting the patient has an active infection Patients with respiratory failure must use a positive pressure ventilator or intubation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival 5 years Survival analysis and Hazard ratio | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of Acute Myeloid Leukemia in Thailand 5 years Number AML patients per normal population | — |
Countries
Thailand
Contacts
Public ContactWeerapat Owattanapanich
Division of Hematology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol Unive
Outcome results
None listed